ACC	Adrenocortical carcinoma
ADCs	Antibody–drug conjugates
ADME	Absorption, Distribution, Metabolism, and Excretion
BLCA	Bladder Urothelial Carcinoma
BRCA	Breast invasive carcinoma
BV	Brentuximab vedotin
CESC	Cervical squamous cell carcinoma and endocervical adenocarcinoma
CHOL	Cholangiocarcinoma
COAD	Colon adenocarcinoma
DAR	drug antibody ratio
DLBC	Lymphoid Neoplasm Diffuse Large B-cell Lymphoma
ESCA	Esophageal carcinoma
EV	Enfortumab vedotin
GBM	Glioblastoma multiforme
GO	Gemtuzumab ozogamicin
HNSC	Head and Neck squamous cell carcinoma
IO	Inotuzumab ozogamicin
KICH	Kidney Chromophobe
KIRC	Kidney renal clear cell carcinoma
KIRP	Kidney renal papillary cell carcinoma
LAML	Acute Myeloid Leukemia
LGG	Brain Lower Grade Glioma
LIHC	Liver hepatocellular carcinoma
LT	Loncastuximab tesirine
LUAD	Lung adenocarcinoma
LUSC	Lung squamous cell carcinoma
MS	Mirvetuximab soravtansine
OV	Ovarian serous cystadenocarcinoma
PAAD	Pancreatic adenocarcinoma
PCP	Physicochemical properties
PCPG	Pheochromocytoma and Paraganglioma
PRAD	Prostate adenocarcinoma
PV	Polatuzumab vedotin
READ	Rectum adenocarcinoma
SARC	Sarcoma
SG	Sacituzumab govitecan
SKCM	Skin Cutaneous Melanoma
SOC	standard of care
STAD	Stomach adenocarcinoma
TAAs	Tumor-associated antigens
TD	Trastuzumab deruxtecan
TE	Trastuzumab emtansine
TF	tissue factor
TGCT	Testicular Germ Cell Tumors
THCA	Thyroid carcinoma
THYM	Thymoma
TPM	transcripts per million
TV	Tisotumab vedotin
UCEC	Uterine Corpus Endometrial Carcinoma
UCS	Uterine Carcinosarcoma